Avalo Therapeutics, Inc. announced the appointment of Stephen Smolinski as Chief Commercial Officer, effective January 3, 2022. As Chief Commercial Officer, Mr. Smolinski will lead Avalo's commercial team including launch readiness initiatives and play a key role in the development and execution of the Company's “go to market” strategy. Prior to joining Avalo, Mr. Smolinski was the Global Head, Immunology Therapeutic Area at Swedish Orphan Biovitrum AB (Sobi™).

Prior to that Mr. Smolinski was Chief Commercial Officer for Selecta Biosciences where he led the commercial efforts related to SEL-212 for Chronic Refractory Gout. He was involved in multiple gene therapy business development deals leading to collaborations and licensing deals with AskBio and Sarepta. Mr. Smolinski served as the Vice President and Head of Sanofi/Genzyme's North American Rheumatology Business Unit, where he led the development of the company's commercialization plans for the rheumatoid arthritis medicine KEVZARA®.